title: Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression.
abstract: A longitudinal cohort study was conducted to define the prevalence and temporal pattern of antibody response to the HIV-2 virion-associated proteins p26gag and Vpx. One hundred and forty-one asymptomatic HIV-2-infected women were enrolled, and followed for up to 11 years. Eighty-one percent of the subjects had antibodies to p26, and 51% to Vpx; response to these two antigens was not correlated. The response to both proteins was determined early in infection, and remained stable over time. The absence of antibodies to p26 was a highly significant predictor of CDC category IV HIV-related disease (p < 0.01) in both univariate and multivariate analysis. Antibody response to Vpx alone was not associated with disease progression. However, those individuals lacking anti-p26 antibodies, and with anti-Vpx antibodies, were six times more likely to be classified as CDC category IV by the end of the study (p < 0.01). This represents the first identification of virus-specific serological markers for HIV-2-related disease progression.
authors.affiliation: Harvard AIDS Institute, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Popper
authors.forename: J L
authors.initials: JL
authors.lastname: Sankalé
authors.forename: I
authors.initials: I
authors.lastname: Thior
authors.forename: T
authors.initials: T
authors.lastname: Siby
authors.forename: R G
authors.initials: RG
authors.lastname: Marlink
authors.forename: S
authors.initials: S
authors.lastname: Mboup
authors.forename: M
authors.initials: M
authors.lastname: Essex
authors.forename: P J
authors.initials: PJ
authors.lastname: Kanki
mesh_terms: D000595:Amino Acid Sequence; D015153:Blotting, Western; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D015683:Gene Products, gag / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood*; D015488:HIV Antigens / Q000235:genetics / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D015498:HIV-2; D006801:Humans; D008137:Longitudinal Studies; D008969:Molecular Sequence Data; D011993:Recombinant Fusion Proteins / Q000235:genetics; D016415:Sequence Alignment; D011477:Sex Work; D013997:Time Factors; D054334:Viral Regulatory and Accessory Proteins / Q000276:immunology*; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D015683:Gene Products, gag; D015483:HIV Antibodies; D015488:HIV Antigens; D011993:Recombinant Fusion Proteins; C074286:VPX protein, Human immunodeficiency virus 2; D054334:Viral Regulatory and Accessory Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C065558:gag protein p26, Human immunodeficiency virus